Imunon Inc. Common Stock (IMNN)
Stock · NASDAQ · Health Care
$1.02as of 10/16/2026
Price chart
Active signals
IMNN Signal Track Record
How signals performed across all stocks →What IMNN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 31 | -0.8% | 48% | October 5, 2026 |
| Volume Spike | 20 | -0.5% | 40% | September 10, 2026 |
| Bollinger Band Breakout | 13 | -14.9% | 15% | March 4, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -8.3% | 25% | October 4, 2024 |
| Any 20-session window (baseline) | -6.7% | 29% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 20
- Website
- imunon.com/
Fundamentals
- 1-day range
- $1.03$1.07
- Market cap
- $6.64M
- P/E (trailing)
- —
- P/E (forward)
- -0.60
- EPS (trailing)
- $-4.42
- Dividend yield
- —
- Beta
- 2.08
- Avg. volume
- 159.4K
How Imunon Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 30, 2023 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Imunon Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IMNNImunon Inc. Common Stock$1.02▼ 3.77%Market cap $6.64MP/E —$0.96$5.29
- ALZNAlzamend Neuro Inc. Common Stock$1.3▲ 1.56%Market cap $6.61MP/E —$0.84$2.68
- CVKDCadrenal Therapeutics Inc. Common Stock$1.09▲ 12.37%Market cap $6.67MP/E —$0.8163$14.35
- XBIOXenetic Biosciences Inc. Common Stock$1.99▼ 1.00%Market cap $6.53MP/E —$1.87$5.28
- FBLGFibroBiologics Inc. Common Stock$0.971▼ 2.90%Market cap $6.79MP/E —$0.62$9.65
- ENVBEnveric Biosciences Inc. Common Stock$1.38▼ 0.72%Market cap $6.28MP/E —$1.17$13.25
- ACXPAcurx Pharmaceuticals Inc. Common Stock$1.1▼ 5.98%Market cap $6.27MP/E —$1.15$7.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMNN Imunon Inc. Common Stock | $6.64M | — | $1.02 | ▼ 3.77% | $0.96$5.29 |
| ALZN Alzamend Neuro Inc. Common Stock | $6.61M | — | $1.3 | ▲ 1.56% | $0.84$2.68 |
| CVKD Cadrenal Therapeutics Inc. Common Stock | $6.67M | — | $1.09 | ▲ 12.37% | $0.8163$14.35 |
| XBIO Xenetic Biosciences Inc. Common Stock | $6.53M | — | $1.99 | ▼ 1.00% | $1.87$5.28 |
| FBLG FibroBiologics Inc. Common Stock | $6.79M | — | $0.971 | ▼ 2.90% | $0.62$9.65 |
| ENVB Enveric Biosciences Inc. Common Stock | $6.28M | — | $1.38 | ▼ 0.72% | $1.17$13.25 |
| ACXP Acurx Pharmaceuticals Inc. Common Stock | $6.27M | — | $1.1 | ▼ 5.98% | $1.15$7.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- IMUNON to Participate in Upcoming Investor ConferencesYahoo · 10/8/2026
- Watching Imunon; Zacks Small-Cap Research Gives Stock $25 Price Valuationbenzinga · 10/1/2026
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · 10/1/2026
- IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian CancerYahoo · 10/1/2026
- IMUNON Converts $1.2 Million of Debt-to-EquityYahoo · 9/29/2026
- Imunon, Inc. (IMNN) Shareholder/Analyst Call - SlideshowSeekingAlpha · 9/24/2026
- IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of PlanYahoo · 9/24/2026
- IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 TrialBenzinga · 9/24/2026
- Imunon, Inc. (IMNN) Shareholder/Analyst Call TranscriptSeekingAlpha · 9/23/2026
Insider Activity
Insider Actions →- Faller Douglas Vincent · September 25, 2026 · Grant4.4K @ $1.41
- Lindborg Stacy · September 25, 2026 · Grant6.7K @ $1.41
- Tardugno Michael H · September 25, 2026 · Grant7.2K @ $1.41
- Faller Douglas Vincent · September 11, 2026 · Grant4.2K @ $1.47
- Lindborg Stacy · September 11, 2026 · Grant5.5K @ $1.47
- Tardugno Michael H · September 11, 2026 · Grant5.8K @ $1.47
- Eylward Susan · August 31, 2026 · Sale2.5K @ $1.56
- Faller Douglas Vincent · August 28, 2026 · Grant3.6K @ $1.6
- Eylward Susan · August 28, 2026 · Grant2.5K @ $1.6
- Lindborg Stacy · August 28, 2026 · Grant6.8K @ $1.6
- Tardugno Michael H · August 28, 2026 · Grant7.4K @ $1.6
- Eylward Susan · August 17, 2026 · Sale2.4K @ $1.63
- Faller Douglas Vincent · August 14, 2026 · Grant3.5K @ $1.65
- Eylward Susan · August 14, 2026 · Grant2.4K @ $1.65
- Lindborg Stacy · August 14, 2026 · Grant6.6K @ $1.65
Institutional Ownership
March 31, 2026
- Total shares held
- 490.3K
- Total value held
- $1.55M
- Institutional holders
- 18
- Unknown348.3K
- Unknown48.1K
- Unknown34.4K
- Unknown33.2K
- Unknown12.1K
- Unknown4.5K
- Unknown3.3K
- Unknown3.0K
- Unknown1.9K
- Unknown1.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Imunon Shares Debt Conversion and Ovarian Cancer Data
Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.
Imunon Shares Debt Conversion and Ovarian Cancer Data. Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.